HAC (Russian)
RSCI (Russian)
EBSCO
DOI (USA)
Ulrichsweb (Ulrich’s Periodicals Directory)
Scientific Indexing Services

Treatment of women with menopausal syndrome: an alternative to menopausal hor-mone therapy

DOI: https://doi.org/10.29296/25877305-2022-07-07
Issue: 
7
Year: 
2022

Professor M. Sergeeva-Kondrachenko, MD
Penza Institute for Postgraduate Training of Physicians, Branch, Russian Medical Acade-my for Continuing Professional Education, Ministry of Health of Russia

Pathological menopause in 26-48% of women is accompanied by vascular, endocrine-metabolic, and neuropsychiatric disorders, which favors the development of somatic disease and substantially reduces quality of life. It is considered as a multifactorial disease, in the development of which the leading role is played by impaired autonomic and hormonal regulation, the decreased adaptive reserves of the hypothalamus and its insufficient adaptability to the changed conditions for the functioning of the hypothalamic-pituitary-ovarian axis. It is always impossible to prescribe menopausal hormone therapy, so a search for alternative therapy for menopausal syndrome remains extremely relevant. In this area, Femoklim (Parafarm, Russia) is one of the promising herbal remedies, an agent that simultaneously affects both triggers of menopausal symptoms, such as estrogen and testos-terone deficiency. The authors give the results of their own study assessing cognitive function changes and quality of life indicators in postmenopausal women using the natural non-hormonal agent Femoklim.

Keywords: 
therapy
menopausal syndrome
quality of life
Femoklim.



References: 
  1. Jones O., Strukov V., Kislov A. et al. Comorbid osteoporosis: challenges and new diagnostic opportunities (Part 2). Vrach. (in Russ.).
  2. Menopauzal’naya gormonoterapiya i sokhranenie zdorov’ya zhenshchin v zrelom vozraste. Klinicheskie rekomendatsii (Protokoly) Ministerstva zdravookhraneniya Rossiiskoi Federatsii. M., 2014; 42 р. (in Russ.).
  3. Sergeeva-Kondrachenko M.Yu., Bolotina T.P. Kachestvo zhizni bol’nykh s sakharnym diabetom 2 tipa. Aktual’nye voprosy diagnostiki, lecheniya i reabilitatsii bol’nykh. Mat-ly XVII nauchno-prakt. konf. s mezhdunar. uchast. Sb. statei. Penza, 2014; s. 170–1 (in Russ.).
  4. Sukhikh G.T., Smetnik V.P., Andreeva E.N. et al. Menopauzal’naya gormonoterapiya i sokhranenie zdorov’ya zhenshchin v zrelom vozraste. Klinicheskie rekomendatsii. M., 2016 (in Russ.).
  5. Khabibulina M.M. The effect of an alternative variant of hormone replacement therapy on cardiac manifestations in metabolically healthy obesity and hypoestrogenemia. Pharmacy. 2022; 71 (4): 46–51 (in Russ.). DOI: 10.29296/25419218-2022-04-07
  6. Yureneva S.V., Il’ina L.M. Prakticheskoe rukovodstvo dlya vrachei po vedeniyu zhenshchin v perekhodnom periode i v postmenopauze (po materialam obnovlennykh rossiiskikh i mezhdunarodnykh rekomendatsii). M.: AO «Bayer», 2017; 99 s. (in Russ.).
  7. Yakovets S.M., Lyzikova Yu.A. Biomedical aspects of menopause. Problemy zdorov’ya i ekologii. 2013; 1 (35): 51–7 (in Russ.).
  8. Baber R.J., Panay N., Fenton A. et al. The IMS Writing Group 2016 IMS Recommendations on women’s midlife health and menopause hormone therapy. Climacteric. 2016; 19 (2): 109–50. DOI: 10.3109/13697137.2015.1129166
  9. Lobo R.A., Davis S.R., De Villiers T.J. et al. Prevention of diseases after menopause. Climacteric. 2014; 17 (5): 540–56. DOI: 10.3109/13697137.2014.933411
  10. Maki P.M. Review article. Verbal memory and menopause. Maturitas. 2015; 82 (3): 288–9. DOI: 10.1016/j.maturitas.2015.07.023
  11. McCarrey A.C., Resnick S.M. Postmenopausal hormone therapy and cognition. Horm Behav. 2015; 74: 167–72. DOI: 10.1016/j.yhbeh.2015.04.018